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Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is one of the most prevalent and lethal cancers
worldwide and mortality mostly results from loco-regional recurrence and metastasis. Despite its significance, our
knowledge on molecular, cellular and environmental mechanisms that drive disease pathogenesis remains largely
elusive, and there are limited therapeutic options, with only negligible clinical benefit.
Methods: We applied global gene expression profiling with samples derived from a recently established mouse
model for oral cancer recurrence and identified a list of genes with differential expression between primary and
recurrent tumors.
Results: One differentially expressed gene codes for Myb-binding protein 1a (MYBBP1A), which is known as a
transcriptional co-regulator that physically interacts with nuclear transcription factors, such as NFB and p53. We
confirmed significantly reduced MYBBP1A protein levels on tissue sections of recurrent mouse tumors compared to
primary tumors by immunohistochemistry, and found aberrant MYBBP1A protein levels also in tumor samples of
HNSCC patients. Interestingly, silencing of MYBBP1A expression in murine SCC7 and in human HNSCC cell lines
elicited increased migration but decreased cell growth.
Conclusion: We provide experimental evidence that MYBBP1A is an important molecular switch in the regulation
of tumor cell proliferation versus migration in HNSCC and it will be a major challenge for the future to proof the
concept whether regulation MYBBP1A expression and/or function could serve as a novel option for anti-cancer
therapy.
Background
Head and neck squamous cell carcinoma (HNSCC) is
the most common type of head and neck cancer primar-
ily affecting the mucosa of the upper aero digestive tract
[1]. Tobacco and alcohol consumption are the main risk
factors for HNSCC and have a multiplicative combined
effect [1]. In recent years, there has been an increase in
the annual incidence of HPV-related HNSCC, suggest-
ing that a subset of HNSCC is a sexual transmitted dis-
ease with distinct pathogenesis and clinical features [2].
In spite of considerable advances in diagnosis, treat-
ment and our understanding of the molecular altera-
tions that occur in the pathogenesis of HNSCC, a high
rate of local recurrences and distant metastasis aggra-
vates the clinical situation, and the 5-year survival rate
of patients with an advanced disease has remained at
approximately 50% [3,4]. Therefore, HNSCC is still a
treatment challenge and better biomarkers are despe-
rately needed to identify patients at high risk for treat-
ment failure and to define novel molecular drug targets
for more effective and less toxic treatment modalities
for patients with advanced tumors [4-6].
The development and use of animal models that clo-
sely resembles the pathogenesis and the histopathology
of HNSCC in humans is essential to expand our
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and to develop and improve novel strategies for transla-
tional anti-cancer research [7]. Recently, we established
an orthotopic floor-of-mouth squamous cell carcinoma
model in mice, in which local recurrences occurred at a
high frequency [8]. In the current study, we applied glo-
bal gene expression profiling with samples of this mouse
model to identify genes with differential expression
between primary and recurrent tumors. One candidate
gene encoded the transcriptional co-regulator
MYBBP1A. MYBBP1A was originally identified as an
interacting partner of c-Myb, a proto-oncogene product
[9]. It is localized mainly in the nucleoli [10] and during
the last years was shown to bind several transcription
factors, such as NFB [11].
Here we provide experimental evidence for a crucial
role of MYBBP1A as an important regulator of tumor
cell proliferation and migration, and that tumor cells
with reduced MYBBP1A expression may represent a
sub-population of slow-cycling but mobile cells impli-
cated in local tumor recurrence and metastasis.
Methods
Animal work and sample preparation
Primary and recurrent mouse tumors were obtained as
described previously [8]. The procedures for performing
animal experiments were in accordance with the princi-
ples and guidelines of the ‘Arbeitsgemeinschaft der
Tierschutzbeauftragten in Baden-Württemberg’and were
approved by the ‘Regierungspräsidium Karlsruhe’,G e r -
many (35-9185.81/G-21/07). Tumor samples for RNA
preparation were immediately frozen in liquid nitrogen
after isolation. For histological analysis, primary and
recurrent tumors samples were embedded in OCT
media (Tissue-Tek, Netherlands) or paraffin and subse-
quently cut in 6 μm sections.
RNA preparation
Total RNA extraction from mouse tumors and human
HNSCC cell lines was performed according to the man-
ufacturer’s instructions using peqGOLD RNAPure™
Reagent (Peq Lab, Erlangen, Germany). Total RNA con-
centration was determined by Nanodrop (Thermo
Scientific, USA).
Global gene expression profiling
Total RNA (1 μg) of primary and recurrent tumor sam-
ples derived from five animals were submitted to the
Genomics Core Facilities of DKFZ (Heidelberg, Ger-
many) for global gene expression profiling based on Illu-
mina technology using whole genome BeadChip Sentrix
arrays (mouse WG-6 v2). Array data GEO accession
number: GSE35377. Data normalization and analysis
was done as described in Supplemental data.
IHC analysis
Paraffin-embedded tissue specimens of HNSCC patients
were provided by the tissue bank of the National Center
f o rT u m o rD i s e a s e( I n s t i t u t eo fP a t h o l o g y ,U n i v e r s i t y
Hospital Heidelberg) after approval by the local institu-
tional review board). Paraffin-embedded mouse tumor
samples were obtained as described before [8]. IHC
staining was performed with the Immunodetection kit
(Vector laboratories, Burlingame, CA) according to
manufacturer’si n s t r u c t i o n sa n da sd e s c r i b e de l s e w h e r e
[12]. Following antibodies were used: Anti-mouse
MYBBP1A (AV37224, Sigma-Aldrich, Germany), anti-
mouse Ki67 (Novacastra), anti-human MYBBP1A
(ab54160, Abcam, UK).
Cell culture
Human HNSCC cell lines were purchased from ATCC.
Cells were maintained in Dulbecco’s (SCC-4, SCC-9,
SCC-25) or Minimum Essential Medium (Fadu, Cal-27)
supplemented with 10% fetal bovine serum (Invitrogen,
Germany), 2 mM L-Glutamine (Invitrogen, Germany)
and Antibiotics (50 μg/ml Penicillin-Streptomycin, Invi-
trogen, Germany) in a humidified atmosphere of 6%
CO2 at 37°C. The SCC-7 cell line was cultured as
described previously [8].
siRNA transfection
Human MYBBP1A-specific RNA-oligos (CAA AGG
AGG UCA UAA GAA AUU) and oligos with scrambled
sequence (GUC GAA UGC GAU UGU ACC GUU)
were purchased from Sigma-Aldrich. Mouse siRNA was
purchased from Santa Cruz Biotechnologies (sc-149729).
The transfection in Cal-27 and in SCC-7 cell lines was
performed using oligofectamine (Invitrogen, Germany)
according to manufacturer’s instructions. Analysis of
human or mouse MYBBP1A expression silencing and all
functional experiments were done 48 hours after
transfection.
Real-Time quantitative polymerase chain reaction
Real-time quantitative polymerase chain reaction (RQ-
PCR) analysis was performed as described previously
[13]. Primers used for RQ-PCR are listed in Additional
file 1: Table S1. Target gene cycle of threshold values
were normalized to the corresponding cycle of threshold
of Hprt (for mouse samples) or LAMIN B (for human
samples) using the change in cycle of threshold method.
Western blot analysis
Isolation of nuclear extracts and Western blot analysis
were performed as described previously [14]. Anti-
human MYBBP1A (ab54160) and HSC70 antibodies
(ab1427) were purchased from Abcam (UK). Anti-
mouse Mybbp1a (sc-133880), anti-E-Cadherin (sc-8426),
Acuña Sanhueza et al. BMC Cancer 2012, 12:72
http://www.biomedcentral.com/1471-2407/12/72
Page 2 of 10anti-Actin (SC-1615) and anti-Histone H1 (sc-8030)
were purchased from Santa Cruz Biotechnology.
Cell migration assay
Cells were plated to reach confluence one day prior the
assessment of the experiment in the migration chambers
(Culture inserts, Ibidi, Germany). Next day, the cells
were treated with 10 μgm l
-1 of Mitomycin C (Sigma-
Aldrich, Germany) for 30 minutes and washed twice
with culture media. Once the chamber was removed
pictures were taken at the time points 18, 24, 36 and 42
hours, and analyzed using the UTHSCSA Image tool.
Cell growth and proliferation assay
Cell growth was assessed by Trypan-blue staining
(Sigma-Aldrich, Germany) and counting the cell number
under the microscope using a Neubauer chamber
(Labor Optik, Germany). Proliferation of Cal-27 and
SCC-7 was analyzed using the BrdU Flow Kit (BD Phar-
migen, Germany) according the manufacturer’si n s t r u c -
tions. FACS analysis was performed using CellQuest Pro
(BD Biosciences, Heidelberg, Germany). according to
the manufacturer’s instructions.
Statistical analysis
Data are expressed as means ± SD of three independent
experiments, each performed in triplicate. Differences
between groups were assessed by unpaired, two-tailed
Student’s t test; P < 0.05 was considered significant
(Chi
2 Test).
Results
Identification of differentially expressed genes in a mouse
model of local oral cancer recurrence
To identify differentially expressed genes, whose expres-
sion might be involved in the formation and mainte-
nance of local recurrence in oral squamous cell
carcinoma, we applied global gene expression profiling
on primary and recurrent tumor samples of an estab-
lished orthotopic floor-of-mouth squamous cell carci-
noma mouse model [8]. As described previously,
primary tumors were generated by injection of murine
SCC-7 cells into the floor-of-mouth of BALB/c-nu mice.
Local recurrences were obtained after microsurgical
removal of primary tumors. Total RNA was isolated
from five pairs of primary tumor and respective local
recurrence and applied to global gene expression analy-
sis using whole genome arrays. Following data normali-
zation we ranked differentially expressed genes
according to their relative transcript levels in primary
tumors and local recurrences of each individual and
selected those genes with altered expression in at least
three out of five tumor pairs for further analysis (Figure
1A). We identified a group of 49 differentially expressed
gene IDs, of which 43 showed enhanced expression and
6 were down-regulated in local recurrences compared to
primary tumors. We selected several genes (e.g. Ovos2,
Smra3, Muc10, Dccp1, Tpsab1, and Mybbp1A) for
quantitative RT-PCR analysis and could confirm altered
transcript levels between primary tumors and local
recurrences (Figure 1B).
MYBBP1A protein expression in primary tumors, local
recurrences and its correlation with proliferation and
migration
One gene that was highly reduced in local recurrences
compared to primary tumors encoded the mouse Myb-
binding protein 1a (Mybbp1a) (Figure 1). To confirm
altered Mybbp1a protein expression we performed
immunohistochemical staining on tissue sections derived
from the orthotopic mouse tumor model. A strong
nuclear staining for Mybbp1a protein was detected in
most tumor cells (84%) of primary tumors, which was
significantly reduced on tissue sections from local recur-
rences (35%) (Figure 2). Accordingly, Mybbp1a protein
expression was detectable in SCC-7 cells in culture (Fig-
ure 3A), which we used for further functional analysis in
vitro. We silenced Mybbp1a expression by siRNA tech-
nology and assessed the proliferative status by flow cyto-
metry. SCC-7 cells with reduced Mybbp1a levels
exhibited impaired proliferation compared to control
transfected cells, 12% and 24% cell in S-phase, respec-
tively (Figure 3B), suggesting a positive correlation
between Mybbp1a protein levels and tumor cell prolif-
eration in primary tumors. In line with this assumption,
staining of tissue sections derived from the mouse
model revealed 44% Ki67-positive in the primary tumor,
while recurrent tumors with decreased immunoreactivity
for Mybbp1a showed a prominent reduction of Ki67
staining (14% of the total cells; Additional file 2: Figure
S1).
Next, we analyzed Mybbp1a-siRNA and control trans-
fected SCC-7 cells in a migration chamber and found a
significant increase in cell migration upon silencing of
Mybbp1a expression (Figure 3C), which was accompa-
nied by reduced E-cadherin protein levels (Figure 3A).
In summary, these data demonstrate an opposing role of
MYBBP1A in SCC-7 proliferation and migration.
Expression and function of MYBBP1A in human HNSCC
cell lines and tumor samples
To further support the opposing role of MYBBP1A in
tumor cell physiology, we analyzed its transcript and
protein levels in well-established human HNSCC cell
lines (Fadu, Cal-27, SCC-4, SCC-9, and SCC-25). Semi-
quantitative RT-PCR analysis revealed comparable tran-
script levels of MYBBP1A in all cell lines (Figure 4A).
However, we found a significant difference in protein
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and Cal-27 cells, but reduced protein levels in SCC-4,
SCC-9 and SCC-25 cells (Figure 4B), suggesting a post-
transcriptional mode of MYBBP1A regulation.
In line with the findings in murine SCC-7 cells, we
found a positive correlation between high MYBBP1A
protein levels and increased growth rate of human
HNSCC cells as shown by quantification of cell growth
over time (Figure 4C). In contrast, high MYBBP1A pro-
tein levels were negatively correlated with the migration
capacity (Figure 4D), further supporting a regulatory
function of MYBBP1A as a promoter of tumor cell pro-
liferation and inhibitor of migration. Moreover, SCC-25
cells with low MYBBP1A levels exhibited a significantly
Figure 1 Differentially expressed genes in recurrent tumors of a mouse model.( A) Heat map of differentially expressed genes between
primary and recurrent tumors of oral squamous cells carcinomas developed in a mouse model. (B) Altered transcript levels between primary
tumors and local recurrences were confirmed for selected genes by quantitative RT-PCR (1 = Ovos2; 2 = Muc10; 3 = Dccp1; 4 = Smra3; 5 =
Tpsa1a; 6 = Mybbp1a). Data for relative transcript levels of selected genes obtained from RQ-PCR analysis and global gene expression profiling
were plotted.
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to high expressing cells, such as mouse SCC-7 or
human Cal-27 cell lines (Additional file 3: Figure S2).
Accordingly, silencing of MYBBP1A expression in Cal-
27 cells by siRNA technology (Figure 5A-B) revealed a
significant decrease in cell proliferation as determined
by BrdU incorporation (Figure 5C) accompanied by
increased migration compared to mock controls (Figure
5D).
Finally, tissue sections of matched pairs of human pri-
mary and recurrent tumors were analyzed by immunohis-
tochemistry. In five out of ten HNSCC patients (50%) a
prominent and nuclear staining of MYBBP1A protein was
easily detected in primary tumors, which was severely
reduced in respective recurrent tumors (Figure 6).
Discussion
In this study, we applied global gene expression profiling
on samples of a well-established mouse model of tumor
recurrence, and identified differentially expressed candi-
date genes some of which have been described pre-
viously in the context of HNSCC development or tumor
recurrence, such as mucins, kallikreins, tryptase alpha/
beta 1, claudin-10 and lactotransferrin [15-20]. We also
provided experimental evidence for the crucial role of
MYBBP1A during malignant progression of HNSCCs.
Figure 2 MYBBP1A is down-regulated in recurrences of squamous cell carcinoma.( A-D) Immunohistochemical analysis of mouse tumor
sections with an anti-Mybbp1a antibody revealed specific staining (red signal) in nuclei of tumor cells. Counterstaining was done using
hematoxylin. Scale bars, 50 μm. (E) Positive stained nuclei were quantified and plotted as percentage total (*** p-value = 0.0001).
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proto-oncogene product interacting protein [9,10]. Sev-
eral findings support the assumption that MYBBP1A is
a key regulator of tumor cell physiology: (I) in the pre-
clinical mouse model of tumor relapse and in matched
pairs of HNSCC patients MYBBP1A showed high
expression in primary tumors which was severely
reduced in recurrent tumor samples, and (II) MYBBP1A
expression in murine SCC-7 cells as well as human
HNSCC cell lines support proliferation but was inversely
correlated with tumor cell migration.
Hitherto, the molecular mechanism resulting in
reduced MYBBP1A protein levels in recurrent tumors
remains elusive and will be a major challenge for the
future. So far, our knowledge on regulation and function
of MYBBP1A protein with regard to physiological and
pathophysiological conditions is limited. Concerning
post-translational modification proteolytic processing of
MYBBP1A has been reported in some cells types [21].
Moreover, MYBBP1A was identified as a novel aurora B
kinase substrate, suggesting an important role of
MYBBP1A phosphorylation in the regulation of its func-
tion [22]. Accordingly, human HNSCC cell lines used in
our study exhibited comparable transcript levels while
expressing different amounts of MYBBP1A protein,
suggesting that MYBBP1A protein levels are at least in
part regulated by posttranslational mechanisms. In line
with this assumption, a pilot study demonstrates regula-
tion of MYBBP1A protein stability by ubiquitination,
since treatment of SCC-25 cells with the proteasome
inhibitor MG-132 resulted in an enrichment of the pro-
tein when compared to untreated cells (data not shown).
Hence, a major challenge for the future will be to unravel
the molecular components involved in this process.
Intriguingly, high levels of MYBBP1A protein were
associated with increased proliferation but reduced
migration and invasion of murine SCC-7 and human
HNSCC cell lines, a phenotype that was reverted by
silencing of MYBBP1A expression. Recent publications
established a critical function for MYBBP1A as an
important regulator of distinct transcription factors,
such as the proto-oncogenes MYB and NFBa sw e l la s
the tumor suppressor p53, implicated in cell cycle con-
trol and carcinogenesis [10,11,23,24]. It is worth to note
that aberrant regulation of p53 and NFBi saf r e q u e n t
event in human HNSCC and critically involved in
tumor cell proliferation and the malignant phenotype
[25,26]. More recently, the molecular mechanism has
been elucidated, how mitotic stress and nucleolar dis-
ruption activates MYBBP1A resulting in acetylation and
Figure 3 Function of Mybbp1a on cell proliferation and migration in murine SCC-7 cells.( A) Murine SCC-7 cells were transfected with
scramble (control) or Mybbp1a-specific siRNA (+siRNA), and reduced expression of Mybbp1a protein was confirmed in nuclear fraction using a
murine anti-Mybbp1a antibody. Histone H1 levels served as internal control of protein lysate quantity and quality. Silencing of Mybbp1a was
accompanied by a reduction of E-Cadherin protein levels and an Actin control reveals equal whole cell lysate loading. (B) Transient Mybbp1a
down-regulation led to a reduction of DNA synthesis quantified by BrdU incorporation (*** p-value = 0.0011). (C) SCC-7 cells with silenced
Mybbp1a levels showed an enhanced migratory phenotype compared to scramble transfected controls (* p-value < 0.03).
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[23,24]. The fact that all HNSCC cell lines used in this
study express no or only mutated p53 suggests that the
physical interaction between MYBBP1A and p53 is not
required for its opposing functions on tumor cell prolif-
eration and migration, and it will be interesting to inves-
tigate the consequence of MYBBP1A over expression
and silencing in primary keratinocytes as well as tumor
cells with functional p53.
Although the underlying molecular mechanism, how
MYBBP1A regulates the tumor cell physiology remains
to be elucidated our data suggest that tumor cells with
reduced MYBBP1A protein expression belong to a sub-
population of slow-cycling cells with high mobility. Con-
cerning the later phenotype, improved migration and
invasion capacity of tumor cells with low or absent
MYBBP1A expression might be, at least in part, due to
a reduction in membrane proteins that are critically
implicated in cell-cell adhesion, such as E-Cadherin.
However, more detailed studies are required to highlight
the molecular function of MYBBP1A under physiologi-
cal and pathological conditions, including cancer. The
existence of a slow-cycling subpopulation of MYBBP1A
negative tumor cells in HNSCC patients could be of
high clinical importance since most current therapeutic
regimens target the rapidly proliferating tumor bulk.
Conclusion
Our data support a model in which MYBBP1A exhibits
opposing functions in the pathogenesis of HNSCC. In
the early phase of HNSCC development MYBBP1A pro-
motes tumor cell proliferation, while in advanced
tumors inactivation of MYBBP1A induces accelerated
tumor cell migration and invasion, and thereby hampers
the loco-regional control by facilitating lymph node
metastasis and tumor recurrence. It will be a major
Figure 4 MYBBP1A expression in human HNSCC cell lines.( A) Comparable levels of MYBBP1A transcripts were detected by semi-quantitative
RT-PCR in different human tumor cell lines. LAMIN B transcript levels served as control for cDNA quality and quantity. (B) Western blot analysis
with nuclear protein extracts revealed strong differences in MYBBP1A protein levels. Detection of HSC70 protein levels served as control for
quality and quantity of protein lysates. (C) Increase in cell numbers of Fadu, Cal-27, SCC-4, SCC-9 and SCC-25 were counted at the indicated time
points and plotted over time (*** p-values < 0.005). (D) In vitro wounding scratch assay revealed a significant higher migration rate for SCC-4,
SCC-9 and SCC-25 cells compared to Fadu and Cal-27 cells. Migration was determined by measuring the closure of the gap over time and
plotted as percentage total of the distance (*** p-values < 0.005).
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the reactivation of MYBBP1A expression could serve as
a novel option for anti-cancer therapy for patients with
advanced HNSCC and thereby ameliorate the therapy
response rate.
Additional files
Probe labeling and illumina sentrix beadchip array
hybridization
Biotin-labeled cRNA samples for hybridization on Illu-
mina Mouse Sentrix-6 BeadChip arrays (Illumina, Inc.)
were prepared according to Illumina’s recommended
sample labeling procedure based on the modified
Eberwine protocol (Eberwine et al., 1992). In brief,
500 ng total RNA was used for complementary DNA
(cDNA) synthesis, followed by an amplification/label-
ing step (in vitro transcription) to synthesize biotin-
labeled cRNA according to the MessageAmp II aRNA
Amplification kit (Ambion, Inc., Austin, TX). Biotin-
16-UTP was purchased from Roche Applied Science,
Penzberg, Germany. The cRNA was column purified
according to TotalPrep RNA Amplification Kit, and
eluted in 80 μl of water. Quality of cRNA was con-
trolled using the RNA Nano Chip Assay on an Agilent
2100 Bioanalyzer and spectrophotometrically quanti-
fied (NanoDrop).
Figure 5 Opposing function of MYBBP1A expression on cell migration and proliferation in human HNSCC Cal-27.s i R N A - m e d i a t e d
silencing of MYBBP1A expression in Cal-27 cells compared to controls (scramble siRNA) was confirmed by RQ-PCR (A) and Western blot analysis
(B). Lamin B transcript levels served as control for cDNA quality and quantity, while detection of HSC70 protein levels served as control for
quality and quantity of protein lysates. Significantly accelerated migration (C) and decreased proliferation (D) was observed upon silencing of
MYBBP1A in Cal-27 cells. Migration was determined as described in Figure 3 and proliferation was quantified by BrdU incorporation and FACS
analysis. The graph represents mean values ± SD of the percentage total of cells in S-phase. ** p-values < 0.05, *** p-values < 0.005.
Figure 6 MYBBP1A protein expression on matched samples of
human primary and recurrent tumors. Representative pictures of
immunohistochemical staining for MYBBP1A levels in a primary
tumor (A) and the respective recurrence are shown (B). Scale bars,
50 μm.
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buffer (Illumina Inc.) at a concentration of 100 ng/μl
cRNA, unsealed in a wet chamber for 20 hours. Spike-in
controls for low, medium and highly abundant RNAs
were added, as well as mismatch control and biotinyla-
tion control oligonucleotides. Microarrays were washed
once in High Temp Wash buffer (Illumina Inc.) at 55°C
and then twice in E1BC buffer (Illumina Inc.) at room
temperature for 5 minutes (in between washed with
ethanol at room temperature). After blocking for 5 min
in 4 ml of 1% (wt/vol) Blocker Casein in phosphate buf-
fered saline Hammarsten grade (Pierce Biotechnology,
Inc., Rockford, IL), array signals were developed by a 10
minutes incubation in 2 ml of 1 μg/ml Cy3-streptavidin
(Amersham Biosciences, Buckinghamshire, UK) solution
and 1% blocking solution. After a final wash in E1BC,
the arrays are dried and scanned.
Additional material
Additional file 1: Table S1. Primers used for RQ-PCR.
Additional file 2: Figure S1. Proliferation characteristics of primary
and recurrent mouse tumors.( A) Ki67 protein expression was analyzed
by immunohistochemistry on tumor sections derived from the surgical
mouse model used in this study. A prominent nuclear staining was
observed both in primary tumors and respective recurrence. (B)
Quantification of positive nuclei revealed a significant decrease in the
amount of Ki67-positive cells in recurrent compared to primary tumors
(p-value: 0.0004). Scale bars, 50 μm.
Additional file 3: Figure S2. Invasive capacity comparison of SCC-7,
Cal-27 and SCC-25. The invasiveness of the cell lines was assessed in
Boyden chambers. SCC-25 shows a higher invasive capacity than the
high MYBBP1A expressing cell lines Cal-27 and SCC-7 (p-value: 0.014) (A).
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